Pfizer Beats Q1 Estimates, Confirms 2026 Projections

Pfizer Exceeds Q1 Expectations, Reaffirms 2026 Outlook Pfizer Inc. reported first-quarter 2026 earnings and revenue that surpassed analyst estimates, leading the pharmaceutical company to reaffirm its full-year 2026 financial outlook. The company announced adjusted earnings per share of 75 cents, exceeding the anticipated 72 cents, and generated $14.45 billion in revenue, surpassing the $13.79 billion forecast by analysts surveyed by LSEG.

This performance was driven by growth in recently launched and acquired products. Pfizer is strategically investing in its pipeline, notably through the $10 billion acquisition of obesity biotech Metsera, to mitigate the impact of declining COVID-19 product sales and revenue erosion from older medications. This acquisition aims to bolster long-term growth prospects.

The company is also prioritizing key data releases throughout 2026, including late-stage trial results for an experimental targeted drug in lung cancer. These initiatives underscore Pfizer's focus on pipeline development and diversification to sustain future revenue streams amidst evolving market dynamics.